CureVac's COVID-19 jab did not turn out what many hoped it would be. That's despite using the same messenger RNA technology as rivals Moderna and BioNTech-Pfizer. CureVac aimed to produce its vaccine primarily for developing countries – as it can be stored more easily than other products. And despite disappointing trial-results the company is sticking to the plan.

Subscribe: [ Ссылка ]

For more news go to: [ Ссылка ]
Follow DW on social media:
►Facebook: [ Ссылка ]
►Twitter: [ Ссылка ]
►Instagram: [ Ссылка ]
Für Videos in deutscher Sprache besuchen Sie: [ Ссылка ]

#CureVac #Covid19 #coronavirus

свернуть